Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
NY Blood Ctr./Bronx CRS
mi
from
New York, NY
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
NY Blood Ctr./Bronx CRS
mi
from
New York, NY
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
University of Rochester Vaccines to Prevent HIV Infection CRS
mi
from
New York, NY
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
University of Rochester Vaccines to Prevent HIV Infection CRS
mi
from
New York, NY
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Penn Prevention Crs
mi
from
Philadelphia, PA
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Penn Prevention Crs
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Vanderbilt Vaccine (VV) CRS
mi
from
Nashville, TN
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Vanderbilt Vaccine (VV) CRS
mi
from
Nashville, TN
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Seattle Vaccine and Prevention CRS
mi
from
Seattle, WA
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Seattle Vaccine and Prevention CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated:  11/7/2017
Unidad de Vacunas IDCP-COIN-DIGECITSS CRS
mi
from
Santo Domingo,
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
Status: Enrolling
Updated: 11/7/2017
Unidad de Vacunas IDCP-COIN-DIGECITSS CRS
mi
from
Santo Domingo,
Click here to add this to my saved trials
Statin Therapy to Improve Atherosclerosis in HIV Patients
Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients
Status: Enrolling
Updated:  11/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
Statin Therapy to Improve Atherosclerosis in HIV Patients
Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients
Status: Enrolling
Updated: 11/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test
Status: Enrolling
Updated:  11/9/2017
The University of Alabama at Birmingham Alabama Vaccine Research Clinic
mi
from
Birmingham, AL
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test
Status: Enrolling
Updated: 11/9/2017
The University of Alabama at Birmingham Alabama Vaccine Research Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test
Status: Enrolling
Updated:  11/9/2017
AIDS Research Alliance
mi
from
Los Angeles, CA
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test
Status: Enrolling
Updated: 11/9/2017
AIDS Research Alliance
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test
Status: Enrolling
Updated:  11/9/2017
AIDS Research Consortium of Atlanta
mi
from
Atlanta, GA
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test
Status: Enrolling
Updated: 11/9/2017
AIDS Research Consortium of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers
Status: Enrolling
Updated:  11/10/2017
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers
Status: Enrolling
Updated: 11/10/2017
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
DASH - Decision Making in Adolescent Sexual Health
Adolescent Decision Making and HIV Risk Avoidance: Neurocognitive Factors
Status: Enrolling
Updated:  11/14/2017
Oregon Health and Science University
mi
from
Portland, OR
DASH - Decision Making in Adolescent Sexual Health
Adolescent Decision Making and HIV Risk Avoidance: Neurocognitive Factors
Status: Enrolling
Updated: 11/14/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
Drug Abuse, Depression and Responses to HIV Counseling
Status: Enrolling
Updated:  11/14/2017
Bellevue Hospital Center
mi
from
New York, NY
Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
Drug Abuse, Depression and Responses to HIV Counseling
Status: Enrolling
Updated: 11/14/2017
Bellevue Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
Drug Abuse, Depression and Responses to HIV Counseling
Status: Enrolling
Updated:  11/14/2017
New York University School of Medicine
mi
from
New York, NY
Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
Drug Abuse, Depression and Responses to HIV Counseling
Status: Enrolling
Updated: 11/14/2017
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico
SBIRT in New Mexico
Status: Enrolling
Updated:  11/15/2017
Friends Research Institute
mi
from
Baltimore, MD
Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico
SBIRT in New Mexico
Status: Enrolling
Updated: 11/15/2017
Friends Research Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents
HIV/Sexually Transmitted Disease (STD) Prevention Interventions for Black Adolescents
Status: Enrolling
Updated:  11/15/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents
HIV/Sexually Transmitted Disease (STD) Prevention Interventions for Black Adolescents
Status: Enrolling
Updated: 11/15/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Connecting Resources for Urban Sexual Health
Connecting Resources for Urban Sexual Health
Status: Enrolling
Updated:  11/17/2017
Downtown Youth Clinic
mi
from
Oakland, CA
Connecting Resources for Urban Sexual Health
Connecting Resources for Urban Sexual Health
Status: Enrolling
Updated: 11/17/2017
Downtown Youth Clinic
mi
from
Oakland, CA
Click here to add this to my saved trials
Reality Check: An HIV Risk Reduction Serial Drama
Reality Check: Evaluation of an HIV Risk Reduction Serial Drama for Black Youth
Status: Enrolling
Updated:  11/20/2017
Annenberg School for Communication, University of Pennsylvania
mi
from
Philadelphia, PA
Reality Check: An HIV Risk Reduction Serial Drama
Reality Check: Evaluation of an HIV Risk Reduction Serial Drama for Black Youth
Status: Enrolling
Updated: 11/20/2017
Annenberg School for Communication, University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Status: Enrolling
Updated:  11/21/2017
Skid Row Housing Trust
mi
from
Los Angeles, CA
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Status: Enrolling
Updated: 11/21/2017
Skid Row Housing Trust
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Status: Enrolling
Updated:  11/21/2017
RAND Corporation
mi
from
Santa Monica, CA
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Status: Enrolling
Updated: 11/21/2017
RAND Corporation
mi
from
Santa Monica, CA
Click here to add this to my saved trials
HIV/STI Prevention Among Black Adolescents With Mental Illnesses (Project GOLD)
HIV/STI Prevention Among Black Adolescents With Mental Illnesses
Status: Enrolling
Updated:  11/27/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
HIV/STI Prevention Among Black Adolescents With Mental Illnesses (Project GOLD)
HIV/STI Prevention Among Black Adolescents With Mental Illnesses
Status: Enrolling
Updated: 11/27/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Predictors of Time to Viremia With an Analytic Treatment Interruption
Predictors of Time to Viremia With an Analytic Treatment Interruption
Status: Enrolling
Updated:  12/1/2017
University of California
mi
from
San Francisco, CA
Predictors of Time to Viremia With an Analytic Treatment Interruption
Predictors of Time to Viremia With an Analytic Treatment Interruption
Status: Enrolling
Updated: 12/1/2017
University of California
mi
from
San Francisco, CA
Click here to add this to my saved trials
Predictors of Time to Viremia With an Analytic Treatment Interruption
Predictors of Time to Viremia With an Analytic Treatment Interruption
Status: Enrolling
Updated:  12/1/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Predictors of Time to Viremia With an Analytic Treatment Interruption
Predictors of Time to Viremia With an Analytic Treatment Interruption
Status: Enrolling
Updated: 12/1/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Stem Cell Transplant for Immunologic or Histiocytic Disorders
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplant for Immunologic or Histiocytic Disorders
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Interaction With HIV Antiretroviral Agents
Potential Pharmacokinetic Interaction of Human Immunodeficiency Virus (HIV) Antiretroviral Agents as Fixed-dose Combinations and Riociguat in HIV Patients
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Boston, MA
Interaction With HIV Antiretroviral Agents
Potential Pharmacokinetic Interaction of Human Immunodeficiency Virus (HIV) Antiretroviral Agents as Fixed-dose Combinations and Riociguat in HIV Patients
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Interaction With HIV Antiretroviral Agents
Potential Pharmacokinetic Interaction of Human Immunodeficiency Virus (HIV) Antiretroviral Agents as Fixed-dose Combinations and Riociguat in HIV Patients
Status: Enrolling
Updated:  12/5/2017
Clinical Research Facility
mi
from
Orlando, FL
Interaction With HIV Antiretroviral Agents
Potential Pharmacokinetic Interaction of Human Immunodeficiency Virus (HIV) Antiretroviral Agents as Fixed-dose Combinations and Riociguat in HIV Patients
Status: Enrolling
Updated: 12/5/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV
A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV
Status: Enrolling
Updated:  12/6/2017
NSU Research Center
mi
from
Miami, FL
A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV
A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV
Status: Enrolling
Updated: 12/6/2017
NSU Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Pilot Study to Evaluate Effects of Atorvastatin on Monocyte Activation in HAART-treated HIV Infected Individuals
Status: Enrolling
Updated:  12/8/2017
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Pilot Study to Evaluate Effects of Atorvastatin on Monocyte Activation in HAART-treated HIV Infected Individuals
Status: Enrolling
Updated: 12/8/2017
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling
A Test of an Intervention to Improve Pap Testing Among Women With HIV
Status: Enrolling
Updated:  12/8/2017
Moore Clinic for HIV Care, Johns Hopkins Hospital
mi
from
Baltimore, MD
The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling
A Test of an Intervention to Improve Pap Testing Among Women With HIV
Status: Enrolling
Updated: 12/8/2017
Moore Clinic for HIV Care, Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy
A Pilot, Open Label, Multi Arm, Single Ctr Study to Evaluate Safety & Tolerability of Escalating Doses of Autologous T Cells Modified With Lentiviral Vectors Expressing High Affinity Gag-specific TCRS in HLA-A02 Patients With HIV
Status: Enrolling
Updated:  12/11/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy
A Pilot, Open Label, Multi Arm, Single Ctr Study to Evaluate Safety & Tolerability of Escalating Doses of Autologous T Cells Modified With Lentiviral Vectors Expressing High Affinity Gag-specific TCRS in HLA-A02 Patients With HIV
Status: Enrolling
Updated: 12/11/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
801 University of California, San Francisco HIV/AIDS CRS
mi
from
San Francisco, CA
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
801 University of California, San Francisco HIV/AIDS CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
The Ponce de Leon Ctr. CRS (5802)
mi
from
Atlanta, GA
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
The Ponce de Leon Ctr. CRS (5802)
mi
from
Atlanta, GA
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Northwestern University CRS (2701)
mi
from
Chicago, IL
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
IHV Baltimore Treatment CRS (4651)
mi
from
Baltimore, MD
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
IHV Baltimore Treatment CRS (4651)
mi
from
Baltimore, MD
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Brigham and Women's Hosp. ACTG CRS (107)
mi
from
Boston, MA
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Massachusetts General Hospital ACTG CRS (101)
mi
from
Boston, MA
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Unc Aids Crs
mi
from
Chapel Hill, NC
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Moses H. Cone Memorial Hospital CRS (3203)
mi
from
Greensboro, NC
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Moses H. Cone Memorial Hospital CRS (3203)
mi
from
Greensboro, NC
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Metro Health CRS (2503)
mi
from
Cleveland, OH
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Metro Health CRS (2503)
mi
from
Cleveland, OH
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Pitt CRS (1001)
mi
from
Pittsburgh, PA
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Pitt CRS (1001)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
The Miriam Hospital ACTG CRS (2951)
mi
from
Providence, RI
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
The Miriam Hospital ACTG CRS (2951)
mi
from
Providence, RI
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
31788 Alabama CRS
mi
from
Birmingham, AL
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
31788 Alabama CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Whitman Walker Health CRS (31791)
mi
from
Washington,
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Whitman Walker Health CRS (31791)
mi
from
Washington,
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Rush Univ. Med. Ctr. ACTG CRS (2702)
mi
from
Chicago, IL
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
Bronx-Lebanon Hosp. Ctr. CRS (31469)
mi
from
Bronx, NY
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
Bronx-Lebanon Hosp. Ctr. CRS (31469)
mi
from
Bronx, NY
Click here to add this to my saved trials
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated:  12/12/2017
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
mi
from
Rochester, NY
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Status: Enrolling
Updated: 12/12/2017
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART
A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of LC002, a DermaVir Vaccine, in HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)
Status: Enrolling
Updated:  12/12/2017
Univ. of California Davis Med. Ctr., ACTU
mi
from
Sacramento, CA
Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART
A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of LC002, a DermaVir Vaccine, in HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)
Status: Enrolling
Updated: 12/12/2017
Univ. of California Davis Med. Ctr., ACTU
mi
from
Sacramento, CA
Click here to add this to my saved trials